| Dr Matthew M Kershisnik, MD | |
|
1400 N 500 E, Logan, UT 84341-2455 | |
| (435) 716-5375 | |
| (843) 284-3401 |
| Full Name | Dr Matthew M Kershisnik |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 1400 N 500 E, Logan, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851363600 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 1831351205 (Utah) | Primary |
| Entity Name | Northern Utah Pathology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053383141 PECOS PAC ID: 6800826660 Enrollment ID: O20050822000404 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
German and Canadian neuroscientists have shown that living in a city or even being raised in one is associated with differences in the way the brain handles stress. They write in Nature that this is the first time researchers have used functional magnetic resonance imaging (fMRI) to identify specific brain regions that are affected by urban life.
Michael F. Holick, PhD, MD, director of the General Clinical Research Unit and professor of medicine, physiology and biophysics at Boston University School of Medicine (BUSM) was selected by the American College of Nutrition (ACN) Awards Committee as the 2011 recipient of the ACN Communication Media Award.
US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne. This will be followed by trials to be held at Adelaide, Brisbane, Perth, Mackay and Sunshine Coast say the sources.
'Tis the season to be jolly and heart healthy. "It is common for us to see an increase in heart-related issues, particularly around Christmas and New Year's," said Brandon Stacey, M.D., a cardiologist at Wake Forest Baptist Medical Center. "It is important to know that if you experience any chest pain or discomfort, seek immediate medical attention or call 911."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew M Kershisnik, MD Po Box 30309, Charleston, SC 29417-0309 Ph: (843) 554-9300 | Dr Matthew M Kershisnik, MD 1400 N 500 E, Logan, UT 84341-2455 Ph: (435) 716-5375 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
German and Canadian neuroscientists have shown that living in a city or even being raised in one is associated with differences in the way the brain handles stress. They write in Nature that this is the first time researchers have used functional magnetic resonance imaging (fMRI) to identify specific brain regions that are affected by urban life.
Michael F. Holick, PhD, MD, director of the General Clinical Research Unit and professor of medicine, physiology and biophysics at Boston University School of Medicine (BUSM) was selected by the American College of Nutrition (ACN) Awards Committee as the 2011 recipient of the ACN Communication Media Award.
US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne. This will be followed by trials to be held at Adelaide, Brisbane, Perth, Mackay and Sunshine Coast say the sources.
'Tis the season to be jolly and heart healthy. "It is common for us to see an increase in heart-related issues, particularly around Christmas and New Year's," said Brandon Stacey, M.D., a cardiologist at Wake Forest Baptist Medical Center. "It is important to know that if you experience any chest pain or discomfort, seek immediate medical attention or call 911."
› Verified 7 days ago
Mark Andrew Benedict, DO Pathology Medicare: Accepting Medicare Assignments Practice Location: 1400 N 500 E, Logan, UT 84341 Phone: 435-716-4103 |